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Background: The aim of our study was to develop and validate the first set of PKU-specific Health-related Quality
of Life (HRQoL) questionnaires that: 1) were developed for patients with PKU and their parents, 2) cover the physical,
emotional, and social impacts of PKU and its treatment on patients’ lives, 3) are age specific (Child PKU-QOL, Adolescent
PKU-QOL, Adult PKU-QOL), 4) enable the evaluation of the HRQoL of children by their parents (Parent PKU-QOL), and 5)
have been cross-culturally adapted for use in seven countries (i.e. France, Germany, Italy, The Netherlands, Spain, Turkey
and the UK).
Methods: The PKU-QOL questionnaires were developed according to reference methods including patients’ , parents’
and healthcare professionals’ interviews; testing in a pilot study (qualitative step in six countries), and linguistic
validation of the finalised pilot versions in Turkish. For finalisation and psychometric validation, the pilot versions were
included in a multicentre, prospective, non-interventional, observational study conducted in 34 sites in France,
Germany, Italy, The Netherlands, Spain, Turkey and the UK. Iterative multi-trait analyses were conducted. Psychometric
properties were assessed (concurrent and clinical validity, internal consistency reliability and test-retest reliability).
Results: Data from 559 subjects (306 patients, 253 parents) were analysed. After finalisation, the PKU-QOL questionnaires
included 40 items (Child PKU-QOL), 58 items (Adolescent PKU-QOL), 65 items (Adult PKU-QOL) and 54 items (Parent
PKU-QOL), distributed in four modules: PKU symptoms, PKU in general, administration of Phe-free protein supplements
and dietary protein restriction. The measurement properties of the Adolescent, Adult and Parent PKU-QOL questionnaires
were overall fairly satisfactory, but weaker for the Child questionnaire.
Conclusions: The four PKU-QOL questionnaires developed for different ages (Child PKU-QOL, Adolescent PKU-QOL,
Adult PKU-QOL), and for parents of children with PKU (Parent PKU-QOL) are valid and reliable instruments for assessing
the multifaceted impact of PKU on patients of different age groups (children, adolescents and adults) and their parents,
and are available for use in seven countries. They are very promising tools to explore how patients’ perceptions evolve
with age, to increase knowledge of the impact of PKU on patients and parents in different countries, and to help
monitor the effect of therapeutic strategies.
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Phenylketonuria (PKU, OMIM 261600) is a rare genetic
disorder (with an incidence of 1 in 10,000 births in
Europe [1]) characterised by a deficiency of the hepatic
enzyme, phenylalanine hydroxylase (PAH, EC 1.14.16.1),
responsible for the conversion of the essential amino
acid phenylalanine (Phe) into tyrosine. The absence of
or deficiency in PAH results in increased blood concen-
trations of Phe and toxic accumulation in the brain. If
left untreated, PKU may lead to intellectual impairment,
deficit in cognitive functions, seizures, behavioural prob-
lems and psychiatric symptoms [2,3]. Historically, PKU
can be classified by Phe level at the time of diagnosis,
with levels 360–1200 μmol/L being classified as mild-
moderate PKU and >1200 μmol/L as classical PKU.
With the implementation of new-born screening pro-
grammes and early diagnosis and treatment, patients with
PKU can develop normally. Current treatment for PKU in-
cludes a life-long diet highly restrictive in Phe, supported
nutritionally with a Phe-free protein supplement (medical
food, metabolic formula, amino acid mixtures), and ex-
cluding high protein foods such as meat, fish, eggs, cheese,
milk products and bread [4]. Recent and on-going devel-
opment of pharmacological treatment tools may allow
modification of dietary restriction, but do not yet consist-
ently allow discontinuation of traditional diet therapy.
However, even when treated, PKU may have an impact
on neurocognitive and psychosocial outcomes. In a meta-
analysis examining neuropsychological outcomes in early
and continuously treated adolescents and adults, Moyle
et al. [5] demonstrated that patients with PKU differed sig-
nificantly from controls on Full-Scale IQ, processing speed,
attention, inhibition, and motor control. Psychological
disorders such as low self-esteem, lower achievement mo-
tivation, decreased autonomy and decreased social compe-
tence have been reported in early-treated children, and
adolescents and adults may be at risk for depressed mood,
generalized anxiety, and social isolation [6,7].
The management of PKU is complex, requiring adher-
ence to diet therapy and Phe-free protein supplement in-
take, regular collection of blood samples, recording of
food intake, and regular visits to the PKU clinic [8]. Ad-
herence to the diet is especially important during the
early childhood years since cognitive outcomes are closely
related to the control of blood phenylalanine levels [9],
and should be maintained through adulthood to protect
from neuropsychological dysfunction [10,11,5,12]. How-
ever, the strict low-Phe diet imposes a burden on patients
and their families and has been associated with dietary
non-compliance, especially in adolescents and young
adults [10,13-15]. Primary obstacles to better adherence
include time constraints and stress associated with food
preparation and record-keeping, and the restrictions im-
posed on social life [13].For years, preventing intellectual impairment has been
the primary goal of PKU treatment. At present, ‘a life as
normal as possible’ is an additional goal of therapy [16],
aiming not only for normal neuropsychological test out-
comes, but also for normal quality of life [12]. Health-
related quality of life (HRQoL) has been defined as a
broad and multidimensional concept representing the pa-
tient’s subjective perception of the impact of his disease
and its treatment(s) on his daily life, physical, psycho-
logical and social functioning and well-being [17]. HRQoL
studies focusing on patients with PKU and their parents
are still scarce [18-22,11,23-27]. Most studies suggest that
the HRQoL of patients with PKU is comparable to that of
the general population [18,19,21,11,23,24,26] with the ex-
ception of a lower HRQoL demonstrated in a group of
Italian children [20], a low score on the cognitive domain
in adults [28], and of severe to moderate distress in 45% of
non-compliant adults patients [18]. Parents of children
with PKU perceive their HRQoL positively overall even
though it may be affected by the emotional and social im-
pact of parenting a child with PKU [22,25]. These studies
all used generic measures of HRQoL, i.e. questionnaires
intended for use irrespective of the underlying disease.
The positive HRQoL results observed in patients with
PKU may, at least in part, be caused by the fact that these
questionnaires may be not be sensitive enough to allow
detection of the specific or subtle problems of patients
with PKU[29-31]. A PKU-specific HRQoL questionnaire
developed with and for patients with PKU will allow their
experience to be more accurately captured, with all its
complexity. Therefore, such an instrument will be able to
detect decrements in specific domains of the life of pa-
tients with PKU as well as potential improvements in
these domains due to therapeutic interventions. In
addition, a PKU-specific questionnaire will make more
sense to patients with PKU, which will certainly lead them
to naturally adhere to the questionnaire and therefore
generate better data.
The aim of our study was to develop and validate the
first set of PKU-specific HRQoL questionnaires that: 1)
were developed with patients with PKU and their care-
givers for children, 2) identify the physical, emotional, and
social impacts characteristic for PKU and its treatment on
patients’ lives, 3) are age specific (Child PKU-QOL, Ado-
lescent PKU-QOL, Adult PKU-QOL), 4) enable the evalu-
ation of the HRQoL of children by their parents (Parent
PKU-QOL), and 5) are cross-culturally adapted to seven
countries (i.e. France, Germany, Italy, The Netherlands,
Spain, Turkey and the UK).
Methods
Development of the questionnaires
The questionnaires were developed in a sequential four
step approach. The first step included exploratory
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healthcare professionals). Interviews were carried out
simultaneously in France, Germany, Spain and the UK
(Table 1). These interviews collected disease-related con-
cepts important to patients and their parents regarding
the impact of PKU and its treatment (i.e. diet and Phe-free
protein supplements) on their life. The thematic analysis
of the qualitative information collected with both patients,
parents and healthcare professionals during this first
phase allowed the creation of conceptual models of the
impact of PKU and its treatment for patients and parents
(Figure 1).
As a second step, question items were generated based
on the conceptual models in six languages (Dutch [The
Netherlands], English [UK], French [France], German
[Germany], Italian [Italy] and Spanish [Spain]). These
formed the content of four questionnaires: one for chil-
dren, adolescents, adults and parents (to assess their
child’s as well as their own HRQoL). After item gener-
ation, the preliminary test versions of the questionnaires
were reviewed and refined by native speakers of each
language to produce the final test versions. The third





Adolescents 13–17 years with PKU 4 4
Adults with PKU 4 4
Parents of children 4–12 years with PKU 4 4
Parents of adolescents 13–17 years with PKU 0 0
Comprehension testing
Children 6–11 years with PKU 3 3
Adolescents 12–17 years with PKU 4 4
Adults with PKU 5 4
Parents of children with PKU 5 5
Linguistic validation
Children 6–11 years with PKU - -
Adolescent 12–17 years with PKU - -
Adults with PKU - -
Parents of children with PKU - -
Psychometric Validation study
Children 9–11 year with PKU 13 19
Adolescents 12–17 years with PKU 10 20
Adults with PKU 18 21
Parents of children ≤8 years with PKU 10 8
Parents of children 9–11 years with PKU 13 19
Parents of adolescents with PKU 10 19acceptability of the questionnaires, the relevance and un-
derstanding of the items and response choices, the com-
prehensiveness of the questions, and opinions regarding
format and layout, and suggestions for rewording of
questionnaires if applicable. Ninety-seven interviews
were conducted in The Netherlands, Germany, Italy,
Spain, France and the UK (Table 1). Overall, the ques-
tionnaires were well accepted and understood by partici-
pants. However, children younger than 9 years of age
showed some difficulty in understanding the question-
naire by themselves, and therefore the age range of the
child version, originally planned for children aged 6–11
years, was narrowed to 9–11 years. Based on partici-
pants’ input and on experts’ experience, the test versions
were modified to produce pilot versions appropriate for
the validation study. The pilot versions of the PKU-QOL
questionnaires (Child, Adolescent, Adult and Parent)
contained 43, 62, 70 and 55 items, respectively. Items
were divided into sections assessing patients’ health,
PKU diet and Phe-free protein supplements, patient’s/
parent’s daily life with PKU, and patient’s/parent’s gen-
eral feeling about PKU. The recall period focused on the
past seven days for all sections except for ‘patient’s/uestionnaire – disposition of subjects by phase and country
Italy Netherlands Spain Turkey UK Total
- - 4 - 6 17
- - 3 - 3 13
- - 4 - 4 16
- - 4 - 4 16
- - 4 - 4 16
- - 3 - 0 3
3 3 3 - 3 18
4 4 4 - 4 24
4 3 4 - 4 24
5 5 5 - 6 31
- - - 3 - 3
- - - 3 - 3
- - - 3 - 3
- - - 3 - 3
15 7 20 14 4 92
26 10 20 20 4 110
22 7 21 8 7 104
8 6 8 6 6 52
15 7 20 4 14 92
26 10 20 4 20 109
Figure 1 Conceptual model of the impact of phenylketonuria (PKU) and its treatment on patients and their parents. From the patients’ perspective,
PKU can have an impact on health status, psychological function, family life and social function. PKU treatment was also reported as having either a
negative impact or no impact (patients who indicated that they did not know any other way of living and had coped with their disease).
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general’. Items had a 5-point Likert-type intensity or fre-
quency response scale with an additional “Does not
apply” or “I don’t…/My child doesn’t” response to some
questions.
The final step of questionnaire development involved
linguistic validation of the pilot versions of the PKU-
QOL questionnaires into Turkish following a standardised
and rigorous process that provides a language version that
is consistent, comparable and conceptually equivalent to
the original instruments [32,33]. As part of this process,
interviews were conducted to test the wording of the
questionnaires with Turkish patients or parents of chil-
dren with PKU (Table 1).
A PKU-QOL Steering Committee (composed of ABu,
AC, ABo and Pr. Peter Burgard) was convened at each
key milestone of the development of the questionnaires
to provide expert insight regarding: development of con-
ceptual models, item generation and comprehension
testing. The PKU-QOL Steering Committee was also
convened for the design and interpretation of the valid-
ation study of the PKU-QOL questionnaire.
Validation study design
From December 2011 to November 2012, a multicentre,
prospective, non-interventional, observational study was
conducted in 34 sites in France, Germany, Italy, The
Netherlands, Spain, Turkey and the UK to finalise and
validate the PKU-QOL questionnaires. More specifically,
the primary objectives of the observational study were:
(1) to define the scoring rules of the four PKU-QOL
questionnaires (how items are grouped into domains);
and (2) to assess the psychometric properties of these
four questionnaires, namely validity (clinical validity andconcurrent validity) and reliability (internal consistency
reliability and test-retest reliability). Characterisation of
the HRQoL of patients with PKU was a secondary object-
ive of the study, with results presented elsewhere [34].
To be included, patients needed to be aged ≥9 years
old, with confirmed diagnosis of PKU and treated for
PKU with a Phe-restricted diet and/or Phe-free protein
supplement and/or pharmacological therapy. To be in-
cluded, parents needed to be parents of at least one
patient aged <18 years old treated for PKU with a Phe-
restricted diet and/or Phe-free protein supplement and/
or pharmacological therapy. Patients and parents were
excluded if they had a significant psychiatric disorder or
conditions preventing their participation as per physi-
cian’s judgment, a history of alcohol or drug abuse in the
12 previous months or current abuse, or if they were
already included in an interventional clinical trial. In
addition, parents were excluded if they were diagnosed
with PKU.
Three groups of patients with PKU were recruited
based on age: children (9–11 years), adolescents (12–17
years) and adults (≥18 years). In addition, parents of in-
cluded children and adolescents were asked to partici-
pate in the study. To supplement this study group and
validate the parent questionnaire for parents of children
of all ages, parents of children <9 years of age were also
included, although children < 9 years were not consid-
ered able to complete the child questionnaire.
Patients/parents were asked to complete the PKU-
QOL questionnaire twice (at baseline and after 2 weeks),
and a generic questionnaire at baseline (Children and
adolescents completed the Pediatric Quality-of-Life Inven-
tory (PedsQL) [35], adult patients completed the Medical
Outcome Survey 36 item Short Form (SF-36) [36] and
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Health Questionnaire 28 item Parent Form (CHQ-
PF28) [37]). They completed the questionnaires at home
and mailed them. For each recruited patient, the phys-
ician was asked to complete a short case report form
with clinical and demographic information on the pa-
tient and parent.
The study was performed in accordance with good
clinical practices and in compliance with local regula-
tory requirements. The appropriate national authorities
and institutional review boards approved the protocol
before study commencement. All patients or their le-
gally authorised representatives provided written in-
formed consent before participation in the study.
The validation study protocol was submitted to the
Conseil National de l’ordre de Médecins (CNOM) in
France, to the Ethik-Kommission an der Medizinischen
Fakultät der Universität Leipzig, Ethikkommission der
Medizinischen Fakultät Heidelberg, Ethik-Kommission
der MHH, Ethik-Kommission des Fachbereichs Medizin der
Johann Wolfgang Goethe- Universität, Ethik-Kommission
der Ärztekammer Westfalen-Lippe und der medizinischen
Fakultät der Westfälischen Wilhelms Universität Münster
and Ethik-Kommission bei der Landesärztekammer Baden-
Württemberg in Germany, to the Comitato Etico della
Azienda Ospedaliero-Universitaria di Bologna, Comitato
Etico per la Sperimentazione Clincal della Provincia di
Vicenza, Comitato Etico per la Sperimentazione della
Azienda Ospedaliera di Padova, Comitato Etico della ASL
NA/1 di Napoli, Comitato di Etica dell 'IRCCS Istituto
Giannina Gaslini de Genova' and Comitato Etico Dell
'Azienda Policlinico Umberto I Di Roma' in Italy, to
the Academisch Medisch Centrum Amsterdam, Univer-
sitair Medisch Centrum Groningen and Academisch
Ziekenhuis Maastricht (AZM) in the Netherlands, to
CCAA Andalucía, CCAA Galicia, CCAA Aragón, CCAA
Baleares, CCAA Pais Vasco and H. Univ Virgen del Rocio
in Spain, to Istanbul University Cerrahpasa Medical Fac-
ulty Ethic Committee in Turkey, to R&D of Glasgow
Royal Infirmary, R&D of Central Manchester University
Hospitals NHS Foundation Trust, R&D of University
Hospitals Bristol and Guy's & St Thomas' Hospital NHS
Foundation Trust in the UK.
Statistical analyses
Scaling structure and the scoring rules of the four PKU-QOL
questionnaires
Item selection and creation of the scoring method were
based on the quality of completion of the items, the dis-
tribution of the responses, and the initial hypothesised
structure of the questionnaires.
Multi-trait analysis [38] was used to test the associ-
ation between single items and the grouping of items
into domains. This method is based on the analysis ofthe correlations between each item and each subscale
according to the following principles: each item should
be strongly correlated with its own scale –correlation
coefficient greater than 0.4 are expected [39] – (item
convergent criterion) and should be more correlated with
its own scale than with others (item discriminant criter-
ion). Iterative applications of the multi-trait analysis
were performed with the following constraints: the
structure should accurately reflect conceptual precon-
ceptions and be kept as similar as possible across the
four questionnaires, and the different areas explored by
the questionnaire (i.e. PKU symptoms, impact of PKU
and its management, dietary protein restrictions, admin-
istration of Phe-free protein supplements) should be
kept separate.
Assessment of psychometric properties
The psychometric validation included assessment of re-
liability (internal consistency reliability and test-retest
reliability) and validity (concurrent validity and clinical
validity). Internal consistency reliability was estimated
using Cronbach’s alpha [40]. Test-retest reliability is
defined as the extent to which the questionnaire leads
to the same results on repeated assessments over
short periods of time. The PKU-QOL questionnaires
were administered twice (i.e. baseline and Week 2) to
allow the assessment of test-retest reliability which
was measured by calculating the Intraclass Correlation
Coefficient (ICC) [41]. A recommended threshold for
reliability coefficients (i.e. Cronbach’s alpha or ICC) is
0.7 [42].
Validity is defined as the accuracy with which a meas-
urement tool measures the concept it is intended to
measure. Concurrent validity was evaluated by investi-
gating the association between PKU-QOL scores and
scores of generic HRQoL questionnaires corresponding
to each age group: the Pediatric Quality-of-Life Inven-
tory (PedsQL) for children and adolescents [35], the 36-
item Short Form (SF-36) Health Survey [36] for adults,
and the Child Health Questionnaire–Parent Form 28
(CHQ-PF28) [37] for parents, using Spearman correl-
ation coefficients. The hypothesis was that domains
measuring related concepts have high correlation levels
while domains measuring different concepts have low
correlations. For clinical validity, the associations be-
tween PKU-QOL scores with severity of PKU (Phe levels
at diagnosis), using a t-test, and with overall assessment
of patient’s health status as rated by the investigator who
recruited the patient (i.e., “In general, how would you
rate the overall health status of your patient?” Poor/Fair/
Good/Very good/Excellent), using an analysis of variance
(ANOVA), were observed. The patients with worse
health status or more severe PKU were expected to have
worse HRQoL.
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Population characteristics in the validation study
Evaluable population
Of the 617 subjects recruited in the study, 559 returned
a PKU-QOL questionnaire and were used in the ana-
lyses: 306 patients with PKU and 253 parents of patients
with PKU. The patient population included 92 children
aged 9 to 11 years, 110 adolescents aged 12 to 17 years
and 104 adults older than 18 years of age. The Parent
population included the parents of 201 subjects from the
child or adolescent population, and 52 additional parents
of children younger than 8 years old. See Table 1 for a
repartition by age group and country.
Demographics
Patients who completed the PKU-QOL were aged be-
tween 9 and 45 years (Table 2). The age distribution in
the child and adolescent populations covered the full age
range (9–11 and 12–17 years), with a mean age in the
middle of this range (9.8 years for children and 14.5 years
for adolescents). The mean age of adult PKU patients
was 25.8 years. Parents were between 24 and 66 years
old, with a mean age of 41.6 years, and their children
had a mean age of 10.7 years. There were about as many
male as female patients in both the child and adolescent
groups (46.7% and 50.9% males, respectively), whereas
there were more females than males in the adult and
parent groups (63.5% and 72.7% females, respectively).
More than two-thirds of the patients (68%) had classic
PKU (characterized by blood Phe level at diagnosis
>1200 μmol/L). This proportion of patients with classic
PKU was fairly stable across all age groups.
Almost all patients were following dietary restriction
(94.1%) and were taking Phe-free protein supplements
(89.2%), and 22.5% were receiving pharmacological ther-
apy, tetrahydrobiopterin (BH4).
Scaling structure and scoring rules
Return rate
The return rate of the PKU-QOL questionnaires was





(n = 92) (n = 110)
Age
(years)
n (missing) 90 (2) 110 (0)
Mean (SD) 9.8 (0.8) 14.5 (1.6)
Min – Max 9.0 – 11.0 12.0 – 17.0





66 (71.7) 75 (68.2)
SD: standard deviation.
*Classical PKU defined as Phe level at diagnosis >1200 μmol/L.acceptability of the questionnaire by patients and their
parents. The return rate was notably lower at both time
points (81% [baseline] and 63% [Week 2]) for parents of
young children (8 years old or younger).
Quality of completion
On average, there were 1.6, 3.0, 1.4 and 2.4 missing
items in the Child PKU-QOL, Adolescent PKU-QOL,
Adult PKU-QOL and Parent PKU-QOL, respectively.
Given the relatively high number of items in the ques-
tionnaires, this represented a small number of missing
data (<5% of the items for all versions). The items that
had a higher level of missing data were those asking
about the ‘attribution’ of a symptom to PKU (e.g. ‘If you
had headaches, do you think it was related to PKU?’).
These were systematically missing for more than 10% of
the patients. This could be due to a difficulty in under-
standing those questions, or in attributing a symptom to
the disease.
Distribution of responses
The distribution of the responses was skewed towards
the most positive response options for a large majority
of items. The items with the most severely skewed
response distribution were listed and reviewed by the
PKU-QOL Steering Committee to determine whether
they were non-informative and could be deleted from
the questionnaire or were considered a key concept that
should be retained in the final questionnaire. Eight items
with severely skewed distribution were identified in the
Child PKU-QOL questionnaire, seven in the Adolescent
PKU-QOL, 14 in the Adult PKU-QOL and two in the
parent versions. Among these, three were deleted after
PKU-QOL Steering Committee appraisal in the Child
PKU-QOL questionnaire (‘Nausea’; ‘Participating in ac-
tivities at school’; ‘Difficulty to do other things due to
burden of care for PKU’), four in the Adolescent PKU-
QOL questionnaire (‘Nausea’; ‘Participating in activities
at school’; ‘Difficulty to do other things due to burden of
care for PKU’, ‘Difficulty starting romantic relationships’),






of the parent population
(n = 104) (n = 253) (n = 253)
101 (3) 244 (9) 251 (2)
25.8 (6.6) 41.6 (6.5) 10.7 (4.2)
18.0 – 45.0 24.0 – 66.0 0.0 – 17.0
38 (36.5) 69 (27.3) 126 (49.8)
67 (64.4) - 172 (68.0)
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other things due to burden of care for PKU’, ‘Difficulty
starting romantic relationships, ‘missing supplements be-
cause of college/university constraints’) and one in the
Parent PKU-QOL questionnaire (‘Nausea’).
Scaling structure
The four questionnaires were structured in four mod-
ules: PKU symptoms, PKU in general, administration of
Phe-free protein supplements and dietary protein restric-
tion (see Table 3 for the final scaling structure of the
four questionnaires). Iterative multitrait analyses led to
the grouping of items in domains within each module.
Results of the final multitrait analyses for each module
of each version of the PKU-QOL questionnaire are pro-
vided as Additional file 1.
The ‘PKU symptoms’ module consists of single-item
symptom scores.
The domains related to the ‘PKU in general’ module
include the following PKU impact scores: practical, so-
cial, emotional and overall impact of PKU. In addition,
additional specific scores were created: anxiety due to
blood tests, and anxiety due to high blood Phe levels.
The adult and parent versions included single-item
scores assessing the level of information on PKU and the
financial impact of PKU, and the parent version included
an extra score for the impact on the parent owing to the
child’s anxiety towards blood tests.
The domains related to the module ’administration of
Phe-free protein supplements’ include scores of adher-
ence to Phe-free protein supplements, score on guilt due
to poor adherence to Phe-free protein supplements, and
scores of impact of Phe-free protein supplements on
daily life and family.
Finally, the domains related to the ‘dietary protein-
restrictions’ module included scores on food temptations
(except for parents), adherence to dietary protein restric-
tions, overall difficulty following dietary restrictions,
guilt if the diet is not followed, social impact of the diet,
practical impact of the diet (except for children), food
enjoyment and taste of specialty low-protein food prod-
ucts. An overall score gathering the two impact scores
was also created.
Scoring rules
For each item of the questionnaire, an item score ranging
from 0 to 4 was obtained based on the response of the pa-
tient. Then, domain scores were calculated by summing
the item scores and applying linear transformation to the
sum to have all domain scores ranging from 0 to 100:
domain score ¼ Sum of item scores within the domain
Number of non missing item scores
within the domain
 25Each domain score is calculated only if at least 70% of
the items of the domain have been completed; otherwise
the domain score was set as missing.
The following interpretation rules were applied for all
domain scores in a range from 0 to 100:
 for symptom scores, a higher score is associated
with more frequent symptoms,
 for adherence scores, a higher score is associated
with a poorer adherence,




Concurrent validity Overall, the pattern of correlation
between the scores of the PKU-QOL questionnaires and
scores of the generic instruments was meaningful: the
highest correlation coefficients were observed between
scores supposed to assess close concepts. In particular,
the ‘Emotional impact of PKU’ scores were well corre-
lated with generic scores of ‘Emotional functioning’ (as
measured by the PedsQL) in children and adolescents
(see Table 4) and with the generic score of ‘Parental
emotional impact’ in parents (as measured by the CHQ-
PF28) (see Table 5). In adults, the PKU-QOL score
‘Overall impact of PKU’ was correlated with the ‘General
health’ score of the SF-36 (see Table 6).
For all PKU-QOL questionnaires, the disease symptom
scores were among the scores with the highest correla-
tions with generic HRQoL measures. This could be ex-
plained by the natural fairly direct relationship between
the symptoms of a chronic disease like PKU and the
HRQoL of patients coping with this disease. Conversely,
the scores related to Phe-free protein supplements or
dietary restrictions tap into domains of patients’ life that
cannot be captured by the generic measures. This also
justifies the need for specific measures of PKU to accur-
ately reflect the impact of the disease.
Clinical validity
Comparison of the PKU-QOL scores according to overall
health status as rated by the investigator
PKU-QOL symptom scores and scores assessing the
impact of PKU, which could be assumed to be related to
a patient’s overall health status, tended to have lower
medians in patients with better rating of health status.
For example, the median ‘Overall impact of PKU’ score
for adults with an ‘excellent’ health status was 18 while
it was 27 for adults with ‘very good’ health status and 40
for those with a ‘good’ health status. In adolescents, the
median ‘Overall impact of PKU’ score was 18 for pa-
tients with an ‘excellent’ health, 20 for those with a ‘very
good’ health and 25 for those with a ‘good’ health. In
Table 3 Final scaling/scoring structure of the four PKU-QOL questionnaires












PKU symptoms Self-health rated status √ √ √
Headaches √ √ √ √
Stomach aches √ √ √ √
Tiredness √ √ √ √
Lack of concentration √ √ √ √
Slow thinking √ √ √ √
Trembling hands √
Irritability √ √ √ √
Aggressiveness √ √ √ √
Moodiness √ √ √ √
Sadness √ √ √ √
Anxiety √ √ √ √
PKU in general Emotional impact of PKU Unfairness having PKU √ √ √ √
Worries about the future √ √ √
Worries about future children √ √ √
Disease acceptance √ √ √ √
Self-esteem √ √ √ √
Practical impact of PKU Burden of care for PKU √ √ √ √
Burden of physician visits √ √ √ √
Maintaining activity at work √ √ √
Time in administrative tasks √ √
Missing work √
Difficulty to do other things due to the burden of care for PKU √
Social impact of PKU Explain situation to others √ √ √ √
Discussing PKU within family √ √ √ √
Difficulty making friends √ √ √ √
Impact on relationship with partner √ √
Maintaining friendship √














Table 3 Final scaling/scoring structure of the four PKU-QOL questionnaires (Continued)
Overall impact of PKU* Items from Emotional, practical and social impact of PKU √ √ √ √
Anxiety – blood tests Anxiety having blood test in the arm √ √ √ √
Anxiety having blood test in the finger √ √ √ √
Impact of child anxiety – blood tests Impact of child anxiety of blood test in the arm on parent √
Impact of child anxiety of blood test in the finger on parent √
Anxiety – Phe levels √ √ √ √
Anxiety – Phe levels during pregnancy √
Financial impact of PKU √ √
Information on PKU √ √
Administration of Phe-free
protein supplements
Adherence to Phe-free protein supplements Frequency of supplement intake √ √ √
Adherence/compliance to supplement √ √ √ √
Missing supplements because of school √
Missing supplements because of work constraints √ √
Guilt if poor adherence to Phe-free protein
supplements
√ √ √ √
Impact of Phe-free protein supplements on family √ √ √ √
Practical impact of Phe-free protein supplements Embarrassment/shame taking supplements √ √ √
Lack of spontaneity/freedom due to supplements √ √ √
Difficulty eating out due to supplements √ √ √
Difficulty travelling, transporting supplements for special event
situations
√ √ √
Taste - Phe-free protein supplements √ √ √
Management of Phe-free protein supplements √
Dietary protein restriction Food temptations Temptation/adherence √ √ √
Temptation not emotionally √ √ √
Adherence to diet Adherence/compliance to the diet √ √ √ √
Eat forbidden things secretly √ √ √
Change in diet because of school/college/university constraints √ √
Change in diet because of work constraints √ √














Table 3 Final scaling/scoring structure of the four PKU-QOL questionnaires (Continued)
Management of diet Difficulty monitoring dietary protein restriction √
Difficulty monitoring the amount of calories √
Sadness to forbid food to child √
Worry that child eats things secretly √
Hard when child has to follow diet in front of others √
Impact of diet on relationship with child √
Practical impact of diet Burden of weighing/estimating quantity of protein in food √ √ √
Lack of spontaneity/freedom due to PKU diet √ √ √
Difficulty eating out due to PKU diet √ √ √
Need to plan meals in advance √ √ √
Time-consuming aspects of the diet √ √ √
Complexity cooking √ √ √
Difficulty travelling, transporting PKU food for special event
situations
√ √ √
Social impact of diet Feeling different because of diet √ √ √
Relationship within family √ √ √
Temptation emotionally √ √ √
Embarrassment/shame following diet √ √ √
Isolation because of diet √ √ √
Cooking for others √
Overall impact of diet* Items from practical and social impact of dietary protein restriction √ √
Overall difficulty following diet √ √ √
Guilt if diet not followed √ √ √ √
Taste of low-protein food √ √ √
Food enjoyment √ √ √ √
In bold*: Overall multi-item scores including items from different domains.














Table 4 Spearman correlation coefficients between child PKU-QOL and adolescent PKU-QOL and PedsQL scores




EF PF SoF ScF EF PF SoF ScF
Self-rated health status - - - - −0.26 −0.23 −0.22 −0.16
Headaches −0.07 −0.25 −0.05 −0.22 −0.23 −0.28 −0.22 −0.26
Stomach aches −0.33 −0.06 −0.06 −0.17 −0.16 −0.23 −0.25 −0.11
Tiredness −0.13 −0.34 −0.21 −0.30 −0.23 −0.22 −0.15 −0.18
Angry −0.38 −0.36 −0.24 −0.30 −0.30 −0.08 −0.27 −0.08
Aggressiveness −0.08 −0.13 −0.00 −0.10 −0.31 −0.20 −0.21 −0.31
Moodiness −0.13 −0.26 −0.11 −0.25 −0.28 −0.10 −0.10 −0.27
Sadness −0.41 −0.33 −0.33 −0.23 −0.31 −0.17 −0.23 −0.16
Anxiety −0.26 −0.05 −0.31 −0.12 −0.27 −0.18 −0.27 −0.10
Lack of concentration −0.15 −0.32 −0.33 −0.36 −0.21 −0.19 −0.27 −0.48
Slow thinking −0.24 −0.45 −0.37 −0.43 −0.32 −0.42 −0.42 −0.36
Emotional impact of PKU −0.45 −0.22 −0.28 −0.33 −0.47 −0.19 −0.31 −0.28
Practical impact of PKU −0.40 −0.24 −0.25 −0.09 −0.29 −0.19 −0.30 −0.28
Social impact of PKU −0.39 −0.38 −0.41 −0.20 −0.35 −0.10 −0.20 −0.15
Overall impact of PKU −0.54 −0.35 −0.41 −0.30 −0.49 −0.21 −0.31 −0.31
Anxiety – blood test −0.13 −0.05 −0.04 0.05 −0.11 −0.16 −0.05 −0.03
Anxiety – blood Phe levels −0.42 −0.25 −0.13 −0.37 −0.37 −0.14 −0.18 −0.25
Adherence to Phe-free protein supplements −0.12 −0.11 0.00 −0.11 −0.13 −0.23 −0.24 −0.26
Practical impact of Phe-free protein supplements −0.23 −0.18 −0.21 −0.16 −0.43 −0.31 −0.36 −0.25
Guilt if poor adherence to Phe-free protein supplements 0.14 0.09 0.01 0.18 −0.11 0.11 0.04 0.08
Relationships within family because of Phe-free protein supplements −0.30 −0.18 −0.18 −0.11 −0.16 −0.11 −0.14 −0.37
Taste – Phe-free protein supplements −0.28 −0.06 −0.10 −0.23 −0.06 0.00 0.08 −0.17
Food temptations −0.32 −0.29 −0.35 −0.14 −0.36 −0.10 −0.24 −0.18
Adherence to dietary protein – restriction −0.03 −0.14 −0.01 −0.11 −0.39 −0.09 −0.29 −0.18
Social impact of dietary protein restriction −0.40 −0.45 −0.40 −0.47 −0.37 −0.19 −0.34 −0.34
Practical impact of dietary protein restriction - - - - −0.44 −0.24 −0.30 −0.40
Overall impact of dietary protein restriction - - - - −0.45 −0.27 −0.33 −0.35
Taste – specialty low-protein food −0.12 0.08 0.13 −0.01 −0.19 −0.03 −0.09 −0.15
Food enjoyment −0.19 −0.23 −0.26 −0.11 0.04 0.03 −0.08 −0.08
Guilt if dietary protein restriction not followed 0.01 −0.08 −0.10 −0.03 −0.24 −0.03 −0.16 −0.03
Overall difficulty following dietary protein restriction −0.32 −0.23 −0.24 −0.21 −0.37 −0.16 −0.19 −0.32
PedsQL: Pediatric Quality-of-Life Inventory; Phe: phenylalanine; PKU: phenylketonuria; QOL: quality of life; EF: Emotional functioning; PF: Physical functioning;
SoF: Social functioning; ScF: School functioning.
Moderate correlations (>0.4) are shown in bold.
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17 for patients with an ‘excellent’ health, 19 for those
with a ‘very good’ health and 28 for those with a ‘good’
health. On the other hand, domain scores which were
not expected to be directly related with global health
status (scores related to the impact of Phe-free protein
supplement intake or dietary protein restriction) showed
little association with patient’s health status as assessed
by the clinician.Comparison of the PKU-QOL scores according to severity
of PKU
No clear association between the PKU-QOL domain
scores assessing the symptoms of PKU or the impact of
PKU and the severity of PKU (as defined by blood Phe
level at diagnosis) were observed. A consistent pattern
emerged in the association between scores assessing the
impact of Phe-free protein supplement and the severity
of PKU: patients with classical PKU reporting a higher
Table 5 Spearman correlation coefficients between Parent PKU-QOL and CHQ-PF28 scores in the parent evaluable
population (n = 253)
CHQ-PF28 scores
PKU-QOL scores PF RP GH BP PiT PiE RE SE MH Be FA FC CH
Child health status −0.24 −0.24 −0.43 −0.26 −0.34 −0.39 −0.09 −0.37 −0.23 −0.37 −0.37 −0.26 0.15
Headaches −0.06 −0.10 −0.29 −0.32 −0.18 −0.21 −0.12 −0.25 −0.29 −0.25 −0.22 −0.16 0.16
Stomach aches −0.11 −0.06 −0.18 −0.40 −0.11 −0.23 −0.02 −0.08 −0.27 −0.15 −0.17 −0.03 0.17
Tiredness −0.24 −0.21 −0.28 −0.28 −0.34 −0.36 −0.19 −0.26 −0.35 −0.28 −0.23 −0.11 −0.00
Lack of concentration −0.10 −0.07 −0.23 −0.23 −0.20 −0.22 −0.28 −0.36 −0.33 −0.57 −0.22 −0.17 −0.06
Slow thinking −0.16 −0.10 −0.29 −0.20 −0.20 −0.23 −0.40 −0.37 −0.36 −0.47 −0.26 −0.17 0.03
Irritability −0.12 −0.09 −0.28 −0.16 −0.28 −0.36 −0.23 −0.42 −0.45 −0.54 −0.27 −0.29 0.03
Aggressiveness −0.16 −0.22 −0.19 −0.12 −0.26 −0.28 −0.31 −0.31 −0.37 −0.49 −0.28 −0.24 −0.09
Moodiness −0.14 −0.18 −0.21 −0.26 −0.32 −0.43 −0.31 −0.40 −0.43 −0.53 −0.37 −0.24 −0.07
Sadness −0.16 −0.10 −0.25 −0.32 −0.36 −0.30 −0.36 −0.38 −0.43 −0.35 −0.28 −0.16 0.03
Anxiety −0.18 −0.15 −0.24 −0.18 −0.24 −0.16 −0.34 −0.39 −0.41 −0.20 −0.21 −0.21 0.01
Emotional impact of PKU −0.14 −0.15 −0.33 −0.21 −0.23 −0.40 −0.04 −0.22 −0.29 −0.26 −0.29 −0.27 −0.03
Practical impact of PKU −0.20 −0.18 −0.35 −0.21 −0.33 −0.39 −0.15 −0.24 −0.37 −0.34 −0.42 −0.25 0.07
Social impact of PKU −0.20 −0.18 −0.29 −0.24 −0.26 −0.35 −0.20 −0.25 −0.33 −0.31 −0.37 −0.36 −0.03
Overall impact of PKU −0.21 −0.20 −0.39 −0.26 −0.31 −0.46 −0.12 −0.29 −0.37 −0.35 −0.44 −0.34 −0.02
Anxiety – blood test −0.15 −0.13 −0.14 −0.05 −0.21 −0.22 −0.03 −0.01 −0.15 −0.08 −0.27 −0.06 0.08
Impact of anxiety – blood test −0.19 −0.20 −0.24 −0.10 −0.26 −0.26 −0.09 0.02 −0.14 −0.05 −0.29 −0.03 0.26
Anxiety – blood Phe levels −0.06 −0.06 −0.25 −0.13 −0.13 −0.42 −0.09 −0.06 −0.28 −0.24 −0.19 −0.09 0.05
Financial impact of PKU −0.12 −0.05 −0.20 −0.19 −0.19 −0.29 −0.06 −0.05 −0.15 −0.26 −0.24 −0.20 0.03
Information on PKU −0.14 −0.19 −0.25 −0.26 −0.14 −0.24 −0.14 −0.30 −0.16 −0.24 −0.19 −0.27 0.00
Adherence to Phe-free protein supplements −0.09 −0.16 −0.10 −0.13 −0.11 −0.08 −0.22 −0.24 −0.21 −0.28 −0.12 −0.07 0.03
Management of Phe-free protein supplements −0.03 −0.12 −0.09 −0.10 −0.28 −0.21 −0.05 −0.07 −0.18 −0.28 −0.22 −0.14 −0.06
Practical impact of Phe-free protein
supplements
−0.15 −0.23 −0.19 −0.12 −0.17 −0.18 −0.04 −0.06 −0.25 −0.10 −0.38 −0.26 −0.03
Guilt if poor adherence to Phe-free protein
supplements
−0.14 −0.07 −0.27 −0.09 −0.10 −0.27 −0.11 0.08 −0.20 −0.10 −0.14 −0.05 0.15
Relationships within family because of Phe-free
protein supplements
−0.17 −0.21 −0.15 −0.26 −0.33 −0.22 −0.15 −0.16 −0.24 −0.34 −0.32 −0.23 −0.02
Adherence to dietary protein restriction −0.04 −0.09 −0.17 −0.08 −0.19 −0.11 −0.14 −0.15 −0.09 −0.24 −0.16 −0.10 0.07
Management of dietary protein restriction −0.12 −0.16 −0.26 −0.25 −0.30 −0.40 −0.24 −0.34 −0.35 −0.49 −0.41 −0.29 −0.04
Practical impact of dietary protein restriction −0.15 −0.24 −0.24 −0.28 −0.30 −0.33 −0.10 −0.30 −0.32 −0.33 −0.46 −0.39 −0.14
Food enjoyment −0.11 −0.06 −0.19 −0.28 −0.21 −0.14 −0.07 −0.26 −0.27 −0.24 −0.28 −0.28 0.07
Guilt if dietary protein restriction not followed −0.15 −0.04 −0.15 −0.07 −0.05 −0.31 −0.12 −0.00 −0.15 −0.07 −0.12 −0.04 0.04
CHQ-PF: Child Health Questionnaire–Parent Form; Phe: phenylalanine; PKU: phenylketonuria; QOL: quality of life; PF: Physical functioning; RP: Role/Social Physical;
GH: General health; BP: Bodily Pain; PiT: Parent impact Time; PiE: Parent impact Emotional; RE: Role/Social Emotional; SE: Self-Esteem; MH: Mental Health;
Be: Behaviour; FA: Family Activity; FC: Family Cohesion; CH: Change in Health.
Moderate correlations (>0.4) are shown in bold.
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adolescent and adult patients with mild/moderate PKU
had a median ‘Practical impact of supplements’ of re-
spectively 6 and 13 while for those with classical PKU
median was 19 in both groups. PKU-QOL scores assessing
the aspects related to the diet were associated to the sever-
ity of PKU in adolescents and children: adolescents andchildren with classical PKU had a slightly poorer adher-
ence to their diet and higher impact (social and emo-
tional). However, this association pattern was not found in
adults.
Detailed results of the clinical validity for the Child,
Adolescent, Adult, and Parent PKU-QOL questionnaires
are provided as Additional files 2, 3, 4, and 5, respectively.
Table 6 Spearman correlation coefficients between Adult PKU-QOL and SF-36 scores in the adult evaluable population
(n = 104)
PKU-QOL scores SF-36 scores
PF RP BP GH VT SF RE MH
Self-rated health status −0.37 −0.22 −0.30 −0.58 −0.57 −0.36 −0.29 −0.50
Headaches −0.20 −0.26 −0.39 −0.31 −0.29 −0.41 −0.30 −0.35
Stomach aches −0.17 −0.19 −0.40 −0.30 −0.34 −0.26 −0.33 −0.37
Tiredness −0.28 −0.34 −0.30 −0.40 −0.52 −0.40 −0.32 −0.39
Lack of concentration −0.25 −0.59 −0.37 −0.40 −0.52 −0.51 −0.56 −0.60
Slow thinking −0.27 −0.36 −0.29 −0.36 −0.32 −0.44 −0.47 −0.43
Trembling hands −0.16 −0.21 −0.19 −0.31 −0.31 −0.19 −0.25 −0.28
Irritability −0.23 −0.44 −0.32 −0.29 −0.20 −0.31 −0.40 −0.39
Aggressiveness −0.22 −0.36 −0.21 −0.24 −0.22 −0.31 −0.31 −0.24
Moodiness −0.21 −0.40 −0.45 −0.38 −0.41 −0.54 −0.50 −0.53
Sadness −0.21 −0.44 −0.48 −0.49 −0.39 −0.61 −0.56 −0.66
Anxiety −0.16 −0.31 −0.26 −0.31 −0.29 −0.37 −0.43 −0.47
Emotional impact of PKU −0.41 −0.31 −0.35 −0.43 −0.34 −0.35 −0.31 −0.39
Practical impact of PKU −0.05 −0.38 −0.18 −0.38 −0.38 −0.38 −0.47 −0.38
Social impact of PKU −0.34 −0.32 −0.30 −0.40 −0.30 −0.48 −0.35 −0.39
Overall impact of PKU −0.27 −0.42 −0.42 −0.53 −0.32 −0.53 −0.45 −0.48
Anxiety – blood test 0.05 −0.03 −0.27 −0.16 −0.12 −0.32 −0.22 −0.25
Anxiety – Phe levels −0.19 −0.11 −0.21 −0.28 −0.19 −0.25 −0.17 −0.15
Anxiety – Phe levels during pregnancy −0.11 0.11 −0.03 −0.02 −0.00 −0.05 0.06 −0.13
Financial impact of PKU −0.11 −0.05 −0.05 0.14 0.03 0.01 0.03 0.08
Information on PKU −0.08 −0.11 −0.15 −0.12 −0.08 −0.17 −0.22 −0.19
Adherence to Phe-free protein supplements −0.10 −0.28 −0.25 −0.14 −0.29 −0.35 −0.38 −0.18
Practical impact of Phe-free protein supplements −0.13 −0.13 −0.11 −0.41 −0.43 −0.33 −0.25 −0.37
Guilt if poor adherence to Phe-free protein supplements −0.12 −0.16 −0.23 −0.22 −0.13 −0.30 −0.13 −0.23
Relationships within family because of Phe-free protein supplements −0.02 −0.01 −0.20 −0.15 −0.13 −0.13 0.01 −0.09
Taste – Phe-free protein supplements 0.07 0.12 0.04 −0.24 −0.25 −0.18 −0.00 0.00
Food temptations −0.14 −0.40 −0.19 −0.21 −0.25 −0.37 −0.31 −0.33
Adherence to dietary protein restriction −0.03 −0.29 −0.13 −0.06 −0.17 −0.24 −0.29 −0.29
Social impact of dietary protein restriction −0.12 −0.40 −0.20 −0.43 −0.44 −0.50 −0.50 −0.49
Practical impact of dietary protein restriction −0.21 −0.25 −0.11 −0.38 −0.59 −0.44 −0.39 −0.46
Overall impact of dietary protein restriction −0.23 −0.33 −0.17 −0.45 −0.57 −0.54 −0.44 −0.49
Taste – specialty low-protein food −0.09 −0.31 −0.27 −0.33 −0.25 −0.34 −0.41 −0.33
Food enjoyment −0.19 −0.28 −0.16 −0.36 −0.34 −0.41 −0.38 −0.29
Guilt if dietary protein restriction not followed −0.17 −0.15 −0.21 −0.30 −0.10 −0.33 −0.12 −0.16
Overall difficulty following dietary protein restriction −0.33 −0.47 −0.21 −0.38 −0.46 −0.46 −0.34 −0.33
Phe: phenylalanine; PKU: phenylketonuria; QOL: quality of life; SF-36: 36-item Short Form; PF: Physical functioning; RP: Role Physical; BP: Bodily Pain; GH: General
health; VT: Vitality; SF: Social Functioning; RE: Role Emotional; MH: Mental Health.
Correlations between Adult PKU-QOL and SF-36 scores were low to moderate. Moderate correlations (>0.4) are shown in bold.
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Internal consistency reliability
Internal consistency reliability of the majority of multi-
item scores in adults, adolescents and parents was accept-
able (above the threshold value of 0.70), even if somescores were not fully satisfactory (practical impact of PKU:
Adolescent, α = 0.47; Adult, α = 0.50; and social impact of
PKU: Adolescent, α = 0.45; Adult, α = 0.63). Reliability co-
efficients of the Child PKU-QOL scores were below the
standards generally used. See Tables 7 and 8.







Cronbach α ICC Cronbach α ICC Cronbach α ICC
Self-rated health status - - - 0.49 - 0.67
Headaches - 0.37 - 0.52 - 0.59
Stomach aches - 0.33 - 0.34 - 0.61
Tiredness - 0.27 - 0.51 - 0.62
Irritability/Anger - 0.45 - 0.53 - 0.42
Aggressiveness - 0.44 - 0.64 - 0.53
Moodiness - 0.47 - 0.59 - 0.66
Sadness - 0.35 - 0.52 - 0.57
Anxiety - 0.44 - 0.70 - 0.60
Lack of concentration - 0.47 - 0.60 - 0.69
Slow thinking - 0.55 - 0.61 - 0.63
Trembling hands - - - - - 0.75
Emotional impact of PKU 0.37 0.60 0.70 0.83 0.71 0.84
Practical impact of PKU 0.43 0.45 0.47 0.75 0.50 0.70
Social impact of PKU 0.59 0.70 0.45 0.83 0.63 0.77
Overall impact of PKU 0.69 0.67 0.80 0.88 0.79 0.84
Anxiety – blood test 0.26 0.64 0.61 0.95 0.77 0.87
Anxiety – blood Phe levels - 0.64 - 0.76 - 0.63
Anxiety – blood Phe levels during pregnancy - - - - - 0.71
Financial impact of PKU - - - - - 0.65
Information on PKU - - - - - 0.60
Adherence to Phe-free protein supplements 0.46 0.48 0.70 0.64 0.67 0.84
Practical impact of Phe-free protein supplements - 0.29 0.82 0.87 0.67 0.67
Guilt if poor adherence to Phe-free protein supplements - 0.60 - 0.59 - 0.67
Relationships within family because of Phe-free protein supplements - 0.72 - 0.69 - 0.57
Taste – Phe-free protein supplements - 0.81 - 0.88 - 0.76
Food temptations 0.63 0.55 0.77 0.74 0.78 0.68
Adherence to dietary protein restriction 0.25 0.43 0.59 0.80 0.81 0.77
Social impact of dietary protein restriction 0.74 0.58 0.88 0.86 0.77 0.83
Practical impact of dietary protein restriction - - 0.74 0.71 0.78 0.70
Overall impact of dietary protein restriction - - 0.74 0.80 0.88 0.79
Taste – specialty low-protein food - 0.47 - 0.57 - 0.73
Food enjoyment - 0.21 - 0.31 - 0.77
Guilt if dietary protein restriction not followed - 0.60 - 0.61 - 0.74
Overall difficulty following dietary protein restriction - 0.55 - 0.59 - 0.54
ICC: Intraclass Correlation Coefficient; Phe: phenylalanine; PKU: phenylketonuria; QOL: quality of life. Reliability coefficients ≥0.70 are set in bold type.
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The analyses of the change in Child PKU-QOL scores
between baseline and Week 2 for the child evaluable
population showed ICCs below the threshold of accept-
ability for the majority of scores (0.21–0.67). The ICC
exceeded the threshold for good test-retest reliability
only for ‘Social impact of PKU’ (0.70), ‘Relationshipswithin family because of supplements’ (0.72) and ‘Taste –
supplements’ (0.81). See Table 7.
The ICC exceeded the threshold for good test-retest
reliability for 14 of 31 Adolescent PKU-QOL scores
(0.70–0.95), for 16 of 33 Adult PKU-QOL scores (0.70–
0.87) and for 11 of 30 Parent PKU-QOL scores (0.70–
0.85). See Tables 7 and 8.
Table 8 Reliability coefficients of the Parent PKU-QOL
questionnaire at baseline in the parent evaluable
population (n = 253)
Parent PKU-QOL scores Cronbach’s α ICC
Child health status - 0.59
Headaches - 0.47







Lack of concentration - 0.63
Slow thinking - 0.60
Emotional impact of PKU 0.63 0.78
Practical impact of PKU 0.74 0.76
Social impact of PKU 0.72 0.80
Overall impact of PKU 0.84 0.84
Anxiety – blood test 0.73 0.85
Impact of anxiety – blood test 0.76 0.78
Anxiety – blood Phe levels - 0.79
Financial impact of PKU - 0.78
Information on PKU - 0.63
Adherence to Phe-free protein supplements - 0.42
Management of Phe-free protein supplements - 0.61
Practical impact of Phe-free protein
supplements
0.77 0.66
Guilt if poor adherence to Phe-free protein
supplements
- 0.59
Relationships within family because of
Phe-free protein supplements
- 0.59
Adherence to dietary protein restriction - 0.29
Management of dietary protein restriction 0.85 0.78
Practical impact of dietary protein restriction 0.82 0.79
Food enjoyment - 0.35
Guilt if dietary protein restriction not followed - 0.70
ICC: Intraclass Correlation Coefficient; Phe: phenylalanine; PKU: phenylketonuria;
QOL: quality of life. Reliability coefficients ≥0.70 are set in bold type.
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The PKU-QOL questionnaires are disease specific ques-
tionnaires developed for and in collaboration with pa-
tients with PKU and parents of children with PKU to
allow assessment of the impact of PKU on the HRQoL
of patients. Three age-specific versions were developed
for children, adolescents and adults with PKU, plus one
version for parents of a child with PKU. All questionnaires
were cross-culturally adapted in seven countries, by either
simultaneous development (for the Netherlands, the UK,France, Germany, Italy and Spain) or proper linguistic val-
idation (for Turkey). The impact of PKU on HRQoL being
assumed to be a culturally sensitive concept, this approach
was applied in an effort to optimise the cross-cultural val-
idity of the measure. Nonetheless, even though this process
is already very sophisticated and warrant a good level of
cross-cultural validity of the instrument, it cannot defin-
itely guarantee that the PKU-QOL is fully cross-culturally
equivalent over all cultures (e.g. some very specific con-
cepts in some cultures may have been missed since ex-
ploratory interviews were not conducted in all countries).
It was also decided from the beginning that the four
questionnaires (child, adolescent, adult, and parent)
would be similarly structured to facilitate use and com-
parison across all ages. While this put a constraint on
the development and validation of the instrument, it is a
clear strength of the questionnaire as it may further
allow following patients longitudinally over time, e.g.
from childhood to adulthood.
The conceptual model underlying the questionnaire was
derived from the experience directly reported by the pa-
tients and parents, complemented by the opinion of
healthcare professionals. The aspects to be assessed by the
questionnaires appeared very clearly: PKU symptoms, im-
pact of PKU on patients’ life and impact of the commonly
used treatment options for PKU (namely dietary protein
restriction and Phe-free protein supplement administra-
tion). Of note, the impact of other therapeutic interven-
tions, in particular pharmacological treatment, did not
appear as central in the experience of patients so was not
included in the PKU-QOL questionnaire. This may be due
to the fact that pharmacological treatment of PKU (i.e.
BH4) was used in a minority of patients (e.g. it was the
case of less than one fourth of patients in the validation
study). Should pharmacological treatment of PKU become
more frequent, an additional module might be developed
for the PKU-QOL questionnaire to assess this aspect.
Hence, the novelty of the PKU-QOL questionnaires
was that they have been developed for and with patients
with PKU and parents of patients with PKU. This pro-
vides a strong advantage over generic HRQoL measures
[19,25,26], questionnaires developed for unspecific chronic
illness (e.g. Ulm Quality-of-Life Inventory for Parents of
chronically ill children) [22] or even the more recent
“PKU-specific” HRQoL questionnaire (PKU-QOLQ) [21],
which had been adapted from a questionnaire used in an-
other condition (juvenile diabetes) and thus had not been
designed fully from the beginning for patients with PKU
specifically. Because it is truly disease specific, the PKU-
QOL questionnaire captures aspects that are important
for PKU patients and their parents and impact their daily
lives (e.g. dietary protein restriction, Phe-free protein sup-
plement administration) that are not addressed by other
HRQoL measures. Hence, the disease specific nature of
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naire by patients (as demonstrated by the very good return
rates and quality of completion in the validation study)
and draws a more accurate picture of the impact of PKU
on patients’ lives.
The measurement properties of the Adolescent, Adult
and Parent PKU-QOL questionnaires were acceptable
overall, although reliability of some scores (in particular
single item scores) was not fully satisfactory. Measure-
ment properties were also clearly weaker for the Child
questionnaire. However, poorer results were expected for
the Child questionnaire because measurement of concepts
as complex as HRQoL is known to be challenging for chil-
dren to self-report [43]. The clinical validity of the PKU-
QOL confirmed the hypothesis that more compromised
HRQoL is found in patients with more severe classical
PKU, and exhibiting worse health status. These findings
tend to show that the PKU-QOL scores seem to capture
the difference in the experience of patients with the man-
agement of their disease (diet and Phe-free protein supple-
ment), as patients with classical PKU have a more strict
management in terms of dietary restriction and Phe-free
protein supplement intakes. Further analysis of PKU-QOL
scores and comparisons according to PKU severity, treat-
ment with pharmacological adjunctive treatment (e.g.
BH4) and health status as assessed by a clinician is pre-
sented in details elsewhere [34].
A remarkable feature of the validation study of the
PKU-QOL was that there were about as many males as
females in the child and adolescent patient samples
while there were substantially more women in both the
adult and parent samples. This may reflect the higher
number of female PKU patients who continue genetics
care as adults, in particular due to the risks associated
with pregnancy in PKU, and the persisting central role
of mothers in the management of children.
A skewed distribution of responses was observed for
most of PKU-QOL items. This finding was not unex-
pected given the overall good health status of the popu-
lation of patients with PKU and limited impact of PKU
or its treatment on the lives of many patients, which
were reported previously and confirmed at all stages of
our research. While this is not an issue in terms of
measurement by the PKU-QOL questionnaire (since it
reflects the reality of patients’ experience), from an ana-
lytical point of view, this may affect the estimation of
correlation coefficients on items (e.g. in the multi-trait
analysis) and even on scores (e.g. in the concurrent val-
idity analysis): This could have weakened the convergent
validity of results and could explain why the correlation
between PKU-QOL scores and generic HRQoL mea-
sures could be regarded at best as moderate.
The validation study of the PKU-QOL had some fea-
tures that potentially affected the results. First, even if thisstudy cohort was large for a disease as rare as PKU (34
sites in seven countries), the samples available for the fi-
nalisation and validation of each version of the PKU-QOL
questionnaire were relatively small for this kind of exer-
cise, which generally requires at least 200 patients. How-
ever, these features were anticipated and addressed by
using simple statistical methods adapted to small samples
(such as rank order correlations). Second, the severity of
PKU was only characterised in the study using Phe level at
diagnosis. This decision was made in an effort to keep the
study as simple as possible with the minimum burden on
the clinicians, but another indicator of severity of PKU,
Phe tolerance, might have allowed complementary ana-
lyses to be performed. Third, the study was conducted in
seven countries with clearly different cultures. This should
be considered as a strength of the PKU-QOL question-
naires as they have now been validated in diverse cultural
settings. However, the cultural differences may also intro-
duce some heterogeneity, adding on to the variability of
the results, and potentially increasing the risk of loss of ro-
bustness of the data.
Future applications of these questionnaires include the
possibility of further targeted evaluation of HRQoL as
impacted by PKU throughout the lifespan. This would
allow better understanding and documentation of the
implications of traditional dietary therapy requirements,
pharmacological treatment (e.g. BH4 supplementation)
and characteristic psychological issues impacting HRQoL.
These questionnaires allow prospective observations of
HRQoL over time and evaluation of evolution of patients’
perceptions with age, as well as the assessment of differ-
ences between parents’ and patients’ perceptions. In
addition, the availability of disease specific PKU-QOL
questionnaires in seven languages will facilitate their
comparative use across population included in inter-
national clinical trials, increase knowledge of the impact
of PKU on the HRQoL of patients and parents in dif-
ferent countries, and allow exploring HRQoL cross-
cultural differences in PKU patients and their parents.
The PKU-QOL questionnaires may also help to monitor
the efficacy of therapeutic and non-therapeutic (e.g. nu-
trition, psychotherapeutic consulting) treatment strat-
egies by assessing their impact on HRQoL. Finally,
clinical use of this questionnaire will help to address
gaps in understanding between physicians, patients and
parents concerning their perceptions of HRQoL as af-
fected by PKU.
A better understanding of the impact of PKU on pa-
tients and their families still requires further research.
To this end, we invite researchers to use the PKU-QOL
questionnaires, which are the first validated questionnaires
specifically developed for this purpose. Further data col-
lection would create an additional body of evidence that
will allow better understanding for patients, parents and
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consistency of care in this chronic disease.
Conclusions
Our study aimed to develop and validate a disease specific
PKU HRQoL questionnaire – the first self-administered
questionnaire designed to comprehensively assess the im-
pact of PKU and its treatment on the HRQoL of patients
and their parents. The questionnaires were developed in
seven languages, in four different populations: children
aged 9–11 years (Child PKU-QOL), adolescents aged 12–
17 years (Adolescent PKU-QOL), adults aged 18 years and
above (Adult PKU-QOL), and parents of patients with
PKU (Parent PKU-QOL). The four questionnaires assess
comprehensively the different factors of life specific to
PKU and the treatment required (such as symptoms and
feelings, daily life, administration of Phe-free protein sup-
plements, and dietary protein restriction), and share a very
similar structure, but still reflect the specific realities of
each of the populations. A comprehensive methodology
was applied to validate the questionnaires in a prospective
validation study demonstrating that all questionnaires had
satisfactory measurement properties and can be used for
evaluation of HRQoL in PKU patients and their parents.
The PKU-QOL questionnaires will allow assessing and
documenting how patients’ perceptions evolve according
to age, increasing our knowledge of the impact of PKU on
patients and parents’ life in different countries, and eventu-
ally helping monitor the efficacy of therapeutic strategies.
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